Skip to main content

Table 3 Medians (inter-quartile ranges) of outcome measures, on enrolment (before PBM treatment) and after PBM treatment for both groups

From: Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study

  On enrolment (n = 12) After 12 weeks of clinic-treatment (n = 12) After 25 or 40 weeks of home-treatment (n = 10)
Mobility tests
 10MWT walk speed (m/s) 1.12 (0.29) 1.70 (0.35)** 1.74 (0.41)
 10MWT stride length (m) 0.52 (0.06) 0.67 (0.11)** 0.75 (0.06)
 TUG (s) 8.0 (1.6) 7.1 (1.3)** 6.58 (1.9)**
 TUG motor (s) 8.6 (3.2) 7.6 (2.0)** 10.4 (2.5)*
 TUG cognitive (s) 10.4 (2.5) 6.9 (2.3)** 9.5 (5.1)**
Dynamic Balance test
 Step test - affected leg (n) 12.0 (5.0) 16.5 (4.5)** 17.5 (5.3)**
 Step test - unaffected leg (n) 12.0 (2.0) 15.5 (4.8)** 19.5 (6.3)**
Cognition test
 MoCA 26 (3.0) 28 (2.0)** 29.9 (1.0)**
Fine Motor Skill tests
 NHPT - affected hand (s) 22.8 (4.0) 27.5 (7.5) 23.9 (7.0)
 NHPT - unaffected hand (s) 23.3 (6.0) 24.0 (7.2) 23.2 (6.2)
 Spiral test - dominant hand (s) 30.9 (11.0) 27.3 (10.6)** 23.4 (9.3)* n = 11
Static Balance tests
 TS affected leg behind (s) 2.0 (6.50) 5.8 (17.00)* 3.9 (26.6) n = 9
 TS unaffected leg behind (s) 1.5 (4.75) 2.75 (19.08) 3.9 (26.8) n = 9
 SLS affected leg raised (s) 2.0 (4.5) 0.8 (3.3) 4.5 (2.8) n = 6
 SLS unaffected leg raised (s) 1.5 (2.0) 1.4 (3.4) 24.5 (21.5) n = 6
  1. Significant improvement in outcome measure compared to before PBM treatment - * p < 0.05 ** p < 0.01
  2. 10MWT 10 m walk test, TUG timed up-and-go, MoCA Montreal Cognitive Assessment, NHPT nine-hole peg test, TS tandem stance (eyes closed), SLS single leg stance (eyes closed)